C5
Complement C5
As of the edition of 20 October 2026, C5 (complement C5, UniProt P01031) has 14 drugs tested at it and 10 companies on the list, 5 on route A and 5 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P01031
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 47
- Disease areas
- Blood and lymph; Immune system; Nervous system; Pregnancy and women's health; Urinary and reproductive; Eye; Cancer; Infections
- Registered trials of its drugs
- 229
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 9 |
| Active | 1 |
| Went quiet | 1 |
| Stopped | 3 |
| Total | 14 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Eculizumab | Marketed | Phase 4 | Ends 2032 |
| Ravulizumab | Marketed | Phase 4 | Ends 2030 |
| Pozelimab | Marketed | Phase 4 | Ends 2035 |
| Zilucoplan | Marketed | Phase 3 | none listed |
| Cemdisiran | Active | Phase 3 | none listed |
| Avacincaptad pegol | Marketed | Phase 4 | none listed |
| Crovalimab | Marketed | Phase 3 | Ends 2036 |
| Vilobelimab | Marketed | Phase 3 | none listed |
| Tesidolumab | Stopped | Phase 2 | none listed |
| Nomacopan | Stopped | Phase 3 | none listed |
| Olendalizumab | Stopped | Phase 2 | none listed |
| Pexelizumab | Went quiet | Phase 3 | none listed |
12 of 14 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Route B | 5 |
| Total on the list | 10 |
The other 7 companies at C5
In the product10 companies in all; 7 are not named here, and no score is.
See the 10 companies at C5, ranked, with the facts behind eachRequest access. Nothing is shown until you do.